文献リスト

1）Hobson RW II, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymp-tomatic carotid stenosis. The Veterans Affairs Cooperative Study Group. N Engl J Med. 1993; 328: 221-7

2）Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995; 273: 1421-8

3）Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: Ran-domised controlled trial. Lancet. 2004; 363: 1491-502

4）Young B, Moore WS, Robertson JT, et al. An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid athero-sclerosis. Stroke. 1996; 27: 2216-24

5）Bond R, Rerkasem K, Rothwell PM. A systematic review of the risks of carotid endarterectomy in relation to the clinical indication and the timing of surgery. Stroke. 2003; 34: 2290-301

6）Naylor AR, Gaines PA, Rothwell PM. Who benefits most from intervention for asymptomatic carotid stenosis: patients or professionals? Eur J Vasc Endovasc Surg. 2009; 37: 625-32

7）Nadareishvili ZG, Rothwell PM, Beletsky V, et al. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. Arch Neurol. 2002; 59: 1162-6

8）Spence JD, Tamayo A, Lownie SP, et al. Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke. 2005; 36: 2373-8

9）Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke. 2009; 40: e573-83

10）Marquardt L, Geraghty OC, Mehta Z, et al. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke. 2010; 41: e11-7

11）Ogata T, Yasaka M, Wakugawa Y, et al. Long-term results of medical and surgical therapy for Japanese patients with moderate carotid stenosis. J Stroke Cerebrovasc Dis. 2012; 21: 24-9

12）Rerkasem K, Rothwell PM. Temporal trends in the risks of stroke and death due to endarte-rectomy for symptomatic carotid stenosis: an up-dated systematic review. Eur J Vasc Endovasc Surg. 2009; 37: 504-11

13）Brott TG, Hobson RW II, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010; 363: 11-23

14）Spence JD, Coates V, Li H, Tamayo A, et al. Effects of intensive medical therapy on micro-emboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol. 2010; 67: 180-6

15）Bock RW, Gray-Weale AC, Mock PA, et al. The natural history of asymptomatic ulcerative lesions of the carotid artery. J Vasc Surg. 1993; 17: 160-9

16）Polak JF, Shemanski L, OLeary DH, et al. Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 or older. Radiology. 1998; 208: 649-54

17）Sebetai MM, Tegos TJ, Nicolaides AN, et al. Hemispheric symptoms and carotid plaque echomorphology. J Vasc Surg. 2000; 31: 39-49

18）Gronholdt ML, Nordestgard BG, Schroedew TV, et al. Ultrasonic echolucent carotid plaques predict feature strokes. Circulation. 2001; 103: 68-73

19）Nighoghossian N, Derex L, Douek P, et al. The vulnerable carotid artery plaque: current imaging method and new perspectives. Stroke. 2005; 36: 2764-72

20）Fisher M, Paganini-Hill A, Martin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke. 2005; 36: 253-7

21）Ogata T, Yasaka M, Wakugawa Y, et al. Mor-phological classification of mobile plaques and their association with early recurrence of stroke. Cerebrvasc Dis. 2010; 30: 606-11

22）Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI-initial results. Stroke. 2006; 37: 818-23

23）Turc G, Oppenheim C, Naggara O, et al. Relationships between recent intraplaque hem-orrhage and stroke risk factors in patients with carotid stenosis: the HIRISC study. Arterioscler Thromb Vasc Biol. 2012; 32: 492-9

24）Naylor AR. What is the current status of invasive treatment of extracranial carotid artery disease? Stroke. 2011; 42: 2080-5

25）Hirt LS. Progression rate and ipsilateral neuro-logical events in asymptomatic carotid stenosis. Stroke. In press

26）Yonas H, Smith HA, Durham SR, et al. Increased stroke risk predicted by compromised cerebral blood flow reactivity. J Neurosurg. 1993; 79: 483-9

27）Silvestrini M, Vernieri F, Pasqualetti P, et al. Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis. JAMA. 2000; 283: 2122-7

28）Ogasawara K, Yukawa H, Kobayashi M, et al. Prediction and monitoring of cerebral hyper-perfusion after carotid endarterectomy by using single-photon emission computerized tomography scanning. J Neurosurg. 2003; 99: 504-10

29）Topakian R, King A, Kwon SU, et al. Ultrasonic plaque echolucency and emboli signals predict stroke in asymptomatic carotid stenosis. Neuro-logy. 2011; 77: 751-8

30）Madani A, Beletsky V, Tamayo A, et al. High-risk asymptomatic carotid stenosis: ulceration on 3D ultrasound vs TCD miroemboli. Neurology. 2011; 77: 744-50

31）Markus HS, King A, Shipley M, et al. Asym-ptomatic embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study (ACES): a prospective observational study. Lancet Neurol. 2010; 9: 663-71

32）Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Sympto-matic Carotid Stenosis (CARESS) trial. Circula-tion. 2005; 111: 2233-40

33）Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisa-tion in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a ran-domised, open-label, blinded-endpoint trial. Lancet Neurol. 2010; 9: 489-97

34）Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005; 36: 782-6

35）Mitsuhashi N, Tanaka Y, Ogawa S, et al. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr J. 2004; 51: 545-50

36）Kato T, Sakai H, Takagi T, et al. Cilostazol prevents progression of asymptomatic carotid artery stenosis in patients with contralateral carotid artery stenting. AJNR Am J Neuroradiol. 2012; 33: 1262-6

37）Côte R, Wolfson C, Solymoss S, et al. Hemostatic markers in patients at risk of cerebral ischemia. Stroke. 2000; 31: 1856-62

38）Rothwell PM, Howard SC, Spence JD. Relation-ship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003; 34: 2583-90

39）Turan TN, Cotsonis G, Lynn MJ, et al. Relation-ship between blood pressure and stroke recur-rence in patients with intracranial arterial stenosis. Circulation. 2007; 115: 2969-75

40）Zanchetti A, Bond MG, Henning M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized double-blind, long-term trial. Circulation. 2002; 106: 2422-7

41）Takai S, Jin D, Sakaguchi M, et al. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens. 2005; 23: 1879-86

42）Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflam-mation. Circulation. 2004; 110: 1103-7

43）Stumpe KO, Agabiti-Rosei E, Zielinski T, et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007; 1: 97-106

44）Stoll G, Bendszus M. Inflammation and athero-sclerosis: novel insights into plaque formation and destabilization. Stroke. 2006; 37: 1923-32

45）Sillesen H, Amarenco P, Hennerich M, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. Stroke. 2008, 39: 3297-302

46）Yamagami H, Sakaguchi M, Furukado S, et al. Statin therapy increases carotid plaque echo-genicity in hypercholesterolemic patients. Ultra-sound Med Biol. 2008; 34: 1353-9

47）Nohara R, Daida H, Hata M, et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Athero-sclerosis Regression Treatment (JART) study. Circ J. 2012; 76: 221-9

48）Cawood AL, Ding R, Napper FL, et al. Eicosa-pentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010; 212: 252-9

49）Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosa-pentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008; 39: 2052-8

50）Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38: 865-73

51）Chang K, Francis SA, Aikawa E, et al. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol. 2010; 30: 1933-9

52）Hirano M, Nakamura T, Kitta Y, et al. Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. Athero-sclerosis. 2009; 203: 483-8

53）Ta NN, Schuyler CA, Li Y, et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011; 58: 157-66

54）Murthy SN, Hilaire RC, Casey DB, et al. The synthetic GLP-1 receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats. Diab Vasc Dis Res. 2010; 7: 138-44

55）Chiuve SE, Rexrode KM, Spiegelman D, et al. Primary prevention of stroke by healthy lifestyle. Circulation. 2008; 118: 947-54

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp